Bio Green Med Solution, Inc.

Regulatory Filings • Aug 13, 2025

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 13, 2025

Date of Report (date of earliest event reported)

Cyclacel Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware	0-50626	91-1707622
(State
or other jurisdiction of incorporation
or organization)	(Commission File
Number)	(I.R.S.
Employer Identification
Number)

Level 10, Tower 11 , Avenue 5, No. 8

Jalan Kerinchi , Kuala Lumpur , Malaysia 592000

(Address of principal executive offices) (Zip code)

(908) 517-7330

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☒ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common Stock, par value
$0.001 per share | CYCC | The Nasdaq Capital Market |
| Preferred Stock, $0.001
par value | CYCCP | The Nasdaq Capital Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 2.02. Results of Operations and Financial Condition.

and

Item 7.01. Regulation FD Disclosure.

The following information is being furnished pursuant to Item 2.02, “Results of Operations and Financial Condition” and Item 7.01, “Regulation FD Disclosure”, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On August 13, 2025, Cyclacel Pharmaceuticals Inc. issued a press release setting forth its second quarter 2025 results. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

Item 9.01. Financial Statements and Exhibits.

| Exhibit
No. | Exhibit |
| --- | --- |
| 99.1 | Press Release of Cyclacel Pharmaceuticals Inc. dated August 13, 2025. |
| 104 | Cover Page Interactive
Data File (embedded within the XBRL document) |

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 13, 2025
By:	/s/
Datuk Dr. Doris Wong Sing Ee
Name:	Datuk Dr. Doris
Wong Sing Ee
Title:	Chief Executive Officer
and Executive Director

Field: Page; Sequence: 3; Options: Last

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kd9KwzAUh59g73AoXpYu6VSkd1rmEDcp2xjexvZMw9qccpLV7ZF8S9PUzhsNgZDk950vf6Iojhb0qGtkeH1YL2GLTVsrh7DGPTKaEn0if3rOwI9rfNfWsTIuTEcwJ8+gZ24Tqfx6SHbaYpWBuJvK2TS9AZFms2soVtGk38/J7HWFxmlVgzIVFEwta3SKz0OFrTqRoeYcTDtkq8lkIBMxbH9BKmQKL9SpT+KDheUyjyZxaJNowXRsfWp+cmh6EuY1Nl5nB/q3h9OUR+uoyQru78xYbRyVB5EIIQvFO1UfcYXNG7KPSpGmUtz/nOJCQEBiuAoUtIqh67k/LP61GjIhP1YfVMibD8X/qQZs9FwEF6P/B9vjo/Ebp8qK9g==